Resigratinib

N/A

Report date: 2025/05/15 20:00:08
NME

Base Information

Drug NameResigratinib
Drug Alias NameKIN-3248KIN-003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 2 antagonists
TargetsFibroblast growth factor receptor 3Fibroblast growth factor receptor 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Transitional CellCholangiocarcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanItaly +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesKinnate Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKinnjiu Biopharma LtdBioDuro LlcKinnate Biopharma Inc +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Transitional CellCholangiocarcinoma +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia